India Advances mRNA Therapeutics in 14th BioE3 Webinar

20 May 2025 CW Team

Launched by the Union Cabinet and the Minister of Science & Technology, the BioE3 Policy focuses on sustainable biomanufacturing across key sectors such as precision therapeutics, including mRNA technology, to drive economic development and affordable healthcare.

The webinar brought together researchers, academics, start-ups, and industry stakeholders to discuss India’s progress and prospects in mRNA therapeutics biomanufacturing.

Dr Alka Sharma, Senior Adviser at DBT, noted that the BioE3 vision seeks to foster high-performance biomanufacturing to drive a global “BioRevolution” anchored in sustainability. She stressed the importance of mRNA therapeutics within this framework and acknowledged the efforts of Indian biotech companies working in this domain. However, she also pointed out persistent sectoral challenges such as product delivery, stability, and reliance on imported raw materials.

Dr Varshneya Singh, Scientist ‘D’ at DBT, provided an overview of the mRNA therapeutics landscape, highlighting its potential in treating cancer, genetic disorders, and infectious diseases. He presented a SWOT analysis of the field and introduced the Call for Proposals for Precision Biotherapeutics – mRNA Therapeutics, a joint DBT-BIRAC initiative to promote innovation and scale-up in this emerging space.

Dr Raghavan Varadarajan from IISc Bangalore detailed the mRNA-LNP vaccine development pipeline, explaining the structure, formulation workflows, and comparative advantages of various lipid nanoparticle delivery systems and microfluidic chip technologies used in mRNA formulation.

Dr Monalisa Chatterji, from Sekkei Bio Pvt Ltd, explored the broader challenges of biologics adoption in India and the immense potential of RNA-based therapeutics. She underscored the urgent need for capacity expansion and greater capital investment to bring these advanced treatments to market at scale.

The webinar concluded with an interactive Q&A session, moderated by officials from DBT and BIRAC. Participants engaged with the panellists on regulatory frameworks, scalability, and innovation strategies in the biomanufacturing of RNA-based therapies.

The event reinforced India’s strategic focus on biotech innovation and the transformative potential of mRNA technologies in reshaping the nation’s healthcare and bioeconomy landscape.

The Department of Biotechnology (DBT), Government of India, in collaboration with the Biotechnology Industry Research Assistance Council (BIRAC), conducted the 14th webinar under the Biofoundry and Biomanufacturing Initiative on 16 May 2025. The session, themed “Biomanufacturing for mRNA Therapeutics”, forms a key part of the BioE3 Policy (Biotechnology for Economy, Environment & Employment), which aims to position India as a global leader in bio-based innovation.Launched by the Union Cabinet and the Minister of Science & Technology, the BioE3 Policy focuses on sustainable biomanufacturing across key sectors such as precision therapeutics, including mRNA technology, to drive economic development and affordable healthcare.The webinar brought together researchers, academics, start-ups, and industry stakeholders to discuss India’s progress and prospects in mRNA therapeutics biomanufacturing.Dr Alka Sharma, Senior Adviser at DBT, noted that the BioE3 vision seeks to foster high-performance biomanufacturing to drive a global “BioRevolution” anchored in sustainability. She stressed the importance of mRNA therapeutics within this framework and acknowledged the efforts of Indian biotech companies working in this domain. However, she also pointed out persistent sectoral challenges such as product delivery, stability, and reliance on imported raw materials.Dr Varshneya Singh, Scientist ‘D’ at DBT, provided an overview of the mRNA therapeutics landscape, highlighting its potential in treating cancer, genetic disorders, and infectious diseases. He presented a SWOT analysis of the field and introduced the Call for Proposals for Precision Biotherapeutics – mRNA Therapeutics, a joint DBT-BIRAC initiative to promote innovation and scale-up in this emerging space.Dr Raghavan Varadarajan from IISc Bangalore detailed the mRNA-LNP vaccine development pipeline, explaining the structure, formulation workflows, and comparative advantages of various lipid nanoparticle delivery systems and microfluidic chip technologies used in mRNA formulation.Dr Monalisa Chatterji, from Sekkei Bio Pvt Ltd, explored the broader challenges of biologics adoption in India and the immense potential of RNA-based therapeutics. She underscored the urgent need for capacity expansion and greater capital investment to bring these advanced treatments to market at scale.The webinar concluded with an interactive Q&A session, moderated by officials from DBT and BIRAC. Participants engaged with the panellists on regulatory frameworks, scalability, and innovation strategies in the biomanufacturing of RNA-based therapies.The event reinforced India’s strategic focus on biotech innovation and the transformative potential of mRNA technologies in reshaping the nation’s healthcare and bioeconomy landscape.

Infrastructure Urban

06 Nov 2025

Concord Control Systems Limited Reports ~85% YoY Growth in H1 FY26

Concord Control Systems Limited (BSE: CNCRD | 543619), India’s leading manufacturer of embedded electronic systems and critical electronic solutions, announced its unaudited financial results for the half year ended September 30, 2025.Financial Highlights – H1 FY26 (YoY Comparison)Revenue from Operations rose to ₹815.45 million, up from ₹497.53 million in H1 FY25, marking a 63.90% year-on-year growth.EBITDA increased to ₹217.34 million, compared to ₹142 million in the same period last year.EBITDA Margin stood at 26.65%, compared to 28.54% in H1 FY25, with the decline attributed to ..

Infrastructure Urban

06 Nov 2025

Gateway Distriparks Announces Q2 FY25 Results

Gateway Distriparks Limited (GDL), one of India’s leading multimodal logistics providers, announced its financial results for the quarter ended 30 September 2025.For Q2, the company reported total revenue of INR 154.8 crore (H1: INR 316.9 crore), EBITDA of INR 20.56 crore (H1: INR 45.65 crore), PBT of INR –4.23 crore (H1: INR –0.28 crore), and PAT of INR –2.91 crore (H1: INR –0.37 crore). The company stated that these numbers reflect the consolidation of accounts following Snowman Logistics transitioning from an associate company to a subsidiary in December 2024.Commenting on the per..

Infrastructure Transport

06 Nov 2025

Last-Mile Connectivity a Prime Focus, Says Ms. Ashwini Bhide,

The IMC Chamber of Commerce and Industry (IMC) hosted a high-impact Managing Committee session today on the theme “Mumbai Metro: Transforming Connectivity and Commuting.” The session featured an insightful address by Ms. Ashwini Bhide, Managing Director, Mumbai Metro Rail Corporation Ltd. (MMRCL), who shared updates on key transport infrastructure developments across Mumbai and the MMR region.Emphasising the city’s critical economic role, Ms. Bhide noted, “Mumbai is the economic powerhouse of Maharashtra, with more than 95% of the region’s population living in urban areas. As Maharas..